RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanomaSara Egea‐Rodriguez, Iris Helfrich|Clinical and Translational Medicine|2025Cited by 2